噻托溴铵联合舒利迭对中重度COPD患者炎症因子、血气指标及肺功能的影响
|
摘要
目的观察噻托溴铵联合舒利迭对中重度COPD患者炎症因子、血气指标及肺功能的影响。方法选取2014年9月至2016年10月于本院治疗的中重度COPD患者96例,根据随机数字表法将其分为对照组和观察组,各48例。对照组使用舒利迭治疗,观察组使用噻托溴铵联合舒利迭治疗。对比两组患者的炎症因子水平、血气指标、肺功能以及不良反应发生情况。结果治疗后,两组PCT、IL-6、CRP水平明显降低,且与对照组相比,观察组上述指标均较对照组低,差异具有统计学意义(P <0. 05);治疗后,两组Pa CO2水平均较治疗前显著降低,Pa O2水平较治疗前明显上升,且观察组Pa CO2水平低于对照组,Pa O2水平高于对照组,差异具有统计学意义(P <0. 05);治疗后,两组患者肺功能各项指标均明显提升,且观察组高于对照组,差异具有统计学意义(P <0. 05);对比两组不良反应发生率,差异无统计学意义(P>0. 05)。结论噻托溴铵联合舒利迭治疗中重度COPD患者具有较好的临床效果,可有效改善患者的血气指标,降低患者气道炎症反应,提升患者肺功能,且具有较好的安全性。
Objective To observe the effect of tiotropium bromide combined with seretide on inflammatory factors,blood gas indexes and pulmonary function in patients with moderate-to-severe COPD. Methods 96 patients with moderate-to-severe COPD from September 2014 to October 2016 were selected and randomly divided into the control group( n = 48) and the observation group( n = 48). The control group was treated with seretide,and the observation group was treated with tiotropium bromide combined with seretide. The inflammatory factors levels,blood gas indexes,pulmonary function,and adverse reactions were compared between the two groups. Results After treatment,the levels of PCT,IL-6 and CRP decreased significantly in the two groups,and the decrease was more pronounced in the observation group than in the control group( P < 0. 05). The Pa CO2 level in the two groups was significantly lower,while the Pa O2 level was significantly higher after treatment than before. And the Pa CO2 level in the observation group was lower than that in the control group,while the Pa O2 level was higher than that in the control group( P < 0. 05). The levels of all indexes of pulmonary function in the two groups increased significantly,and they were obviously higher in the observation group than in the control group( P < 0. 05). There was no statistically significant difference in the incidence of adverse reactions between the two groups( P > 0. 05). Conclusion Tiotropium bromide combined with seretide has good clinical effect for patients with moderate-to-severe COPD,and it can effectively improve blood gas indexes,reduce airway inflammatory response and improve pulmonary function,with high safety.
Objective To observe the effect of tiotropium bromide combined with seretide on inflammatory factors,blood gas indexes and pulmonary function in patients with moderate-to-severe COPD. Methods 96 patients with moderate-to-severe COPD from September 2014 to October 2016 were selected and randomly divided into the control group( n = 48) and the observation group( n = 48). The control group was treated with seretide,and the observation group was treated with tiotropium bromide combined with seretide. The inflammatory factors levels,blood gas indexes,pulmonary function,and adverse reactions were compared between the two groups. Results After treatment,the levels of PCT,IL-6 and CRP decreased significantly in the two groups,and the decrease was more pronounced in the observation group than in the control group( P < 0. 05). The Pa CO2 level in the two groups was significantly lower,while the Pa O2 level was significantly higher after treatment than before. And the Pa CO2 level in the observation group was lower than that in the control group,while the Pa O2 level was higher than that in the control group( P < 0. 05). The levels of all indexes of pulmonary function in the two groups increased significantly,and they were obviously higher in the observation group than in the control group( P < 0. 05). There was no statistically significant difference in the incidence of adverse reactions between the two groups( P > 0. 05). Conclusion Tiotropium bromide combined with seretide has good clinical effect for patients with moderate-to-severe COPD,and it can effectively improve blood gas indexes,reduce airway inflammatory response and improve pulmonary function,with high safety.
引文
[1]刘娅钦,马丽,刘琳.慢性阻塞性肺疾病发病机制的研究进展[J].临床肺科杂志,2016,21(6):1113-1117.
[2]李宏,阳甜,杨岚.慢性阻塞性肺疾病患者肺部感染血清炎性因子变化研究[J].中华医院感染学杂志,2014,24(1):17-18,27.
[3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[S].中华结核和呼吸杂志,2013,36(4):255-264.
[4]黄冬妹,何志义.慢性阻塞性肺疾病抗炎治疗研究新进展[J].重庆医学,2015,44(14):1982-1985.
[5]史碧君,张涛.慢性阻塞性肺疾病流行病学研究进展[J].浙江预防医学,2015,27(4):366-369.
[6]张敏.慢性阻塞性肺疾病表型临床意义的研究进展[J].实用医院临床杂志,2016,13(1):153-155.
[7]罗志成,吴国振,袁星.慢性阻塞性肺疾病治疗药物研究进展[J].药学实践杂志,2017,35(3):201-204,242.
[8]吴桦,尚立群,王水利,等.噻托溴铵联合舒利迭治疗稳定期中重度慢性阻塞性肺疾病患者的效果观察[J].中国综合临床,2014,30(7):706-708.
[9]党建辉.噻托溴铵粉吸入剂和沙美特罗替卡松联合使用治疗慢性阻塞性肺疾病的研究[J].检验医学与临床,2017,14(13):1940-1942.
[10]李贵芳.舒利迭联合噻托溴铵治疗对慢性阻塞性肺疾病患者肺功能影响[J].现代中西医结合杂志,2014,23(30):3353-3355.
[11]赵洪.噻托溴铵联合大剂量舒利迭治疗重度支气管哮喘合并慢性阻塞性肺疾病的疗效及安全性[J].安徽医药,2015,19(8):1593-1595.
[12]吴晓虞,何六涛,陈华春.噻托溴铵联合舒利迭治疗慢性阻塞性肺疾病稳定期患者的临床疗效研究[J].中国生化药物杂志,2017,37(5):229-231.
[2]李宏,阳甜,杨岚.慢性阻塞性肺疾病患者肺部感染血清炎性因子变化研究[J].中华医院感染学杂志,2014,24(1):17-18,27.
[3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[S].中华结核和呼吸杂志,2013,36(4):255-264.
[4]黄冬妹,何志义.慢性阻塞性肺疾病抗炎治疗研究新进展[J].重庆医学,2015,44(14):1982-1985.
[5]史碧君,张涛.慢性阻塞性肺疾病流行病学研究进展[J].浙江预防医学,2015,27(4):366-369.
[6]张敏.慢性阻塞性肺疾病表型临床意义的研究进展[J].实用医院临床杂志,2016,13(1):153-155.
[7]罗志成,吴国振,袁星.慢性阻塞性肺疾病治疗药物研究进展[J].药学实践杂志,2017,35(3):201-204,242.
[8]吴桦,尚立群,王水利,等.噻托溴铵联合舒利迭治疗稳定期中重度慢性阻塞性肺疾病患者的效果观察[J].中国综合临床,2014,30(7):706-708.
[9]党建辉.噻托溴铵粉吸入剂和沙美特罗替卡松联合使用治疗慢性阻塞性肺疾病的研究[J].检验医学与临床,2017,14(13):1940-1942.
[10]李贵芳.舒利迭联合噻托溴铵治疗对慢性阻塞性肺疾病患者肺功能影响[J].现代中西医结合杂志,2014,23(30):3353-3355.
[11]赵洪.噻托溴铵联合大剂量舒利迭治疗重度支气管哮喘合并慢性阻塞性肺疾病的疗效及安全性[J].安徽医药,2015,19(8):1593-1595.
[12]吴晓虞,何六涛,陈华春.噻托溴铵联合舒利迭治疗慢性阻塞性肺疾病稳定期患者的临床疗效研究[J].中国生化药物杂志,2017,37(5):229-231.